PROVECTUS BIOPHARMACEUTICALS, INC.
PVCT · OTCMCIK 315545fmd_0KQXRV3817F2Y4MAN6VP6HCM7KManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2002 to Sep 30, 2026, 75 periods
Latest annual · FY2025
Millions- Total revenues
- 0
- Operating income
- (5)
- Net income
- (5)
Latest quarter · Q3 FY2026
Millions- Operating income
- (1)
- Net income
- (1)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- -30.2%
- Revenue, 5 yearsFY2020 to FY2025
- n/m
- Net income, 5 yearsFY2020 to FY2025
- n/m
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $336,108 | $617,140 | -45.5% | 10-K 2026-03-26 · proof |
| Operating income | -$5.3 million | -$4.5 million | 10-K 2026-03-26 · proof | |
| Net income | -$5.4 million | -$4.7 million | 10-K 2026-03-26 · proof | |
| Cash from operating activities | -$3.3 million | -$3.3 million | 10-K 2026-03-26 · proof | |
| Total assets | $697,502 | $1 million | -30.7% | 10-K 2026-03-26 · proof |
| Total liabilities | $7 million | $7 million | +0.4% | 10-K 2026-03-26 · proof |
| Cash and cash equivalents | $251,291 | $307,442 | -18.3% | 10-K 2026-03-26 · proof |
- What was PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)'s revenue in fiscal 2025?
- PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported revenue of $336,108 for fiscal 2025 (the year ended Dec 31, 2025), against $617,140 the year before (-45.5%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What was PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)'s operating income in fiscal 2025?
- PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported operating income of -$5.3 million for fiscal 2025 (the year ended Dec 31, 2025), against -$4.5 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What was PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)'s net income in fiscal 2025?
- PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported net income of -$5.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$4.7 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What was PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)'s cash from operating activities in fiscal 2025?
- PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported cash from operating activities of -$3.3 million for fiscal 2025 (the year ended Dec 31, 2025), against -$3.3 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What are PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)'s total assets?
- As of Dec 31, 2025, PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported total assets of $697,502, against $1 million a year earlier (-30.7%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What are PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)'s total liabilities?
- As of Dec 31, 2025, PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported total liabilities of $7 million, against $7 million a year earlier (+0.4%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What are PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)'s cash and cash equivalents?
- As of Dec 31, 2025, PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported cash and cash equivalents of $251,291, against $307,442 a year earlier (-18.3%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:PVCT&period_type=annual&limit=5"Information only, not investment advice.